Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EMG and Delta Function in Standard RTSA vs Lateralization

NCT: NCT07464977 · NOT_YET_RECRUITING

NCT IDNCT07464977
StatusNOT_YET_RECRUITING
Start Date2026-06
Completion2027-12

Brief Summary

Reverse total shoulder arthroplasty (RTSA) is a well-established method to treat patients with irreparable rotator cuff tears and glenohumeral osteoarthritis. The biomechanical principle implies a medialization and distalization of the center of rotation (COR). Deficiencies in internal and external rotation constitute frequently encountered functional problems. Some studies showed reduced activation of the posterior deltoid in EMG measurements, which may explain the inability to compensate these movements. Lateralized prosthetic designs demonstrated increased external rotation through an alteration of the deltoid's lever arm. The aim of the study is to investigate the impact of lateralization on functional outcome and deltoid EMG activity in comparison to a standard implantation technique.

Frequently Asked Questions

What is EMG and Delta Function in Standard RTSA vs Lateralization?

EMG and Delta Function in Standard RTSA vs Lateralization is a clinical trial registered under NCT07464977. Current status: NOT_YET_RECRUITING.

What is the status of NCT07464977?

The current status of NCT07464977 (EMG and Delta Function in Standard RTSA vs Lateralization) is: NOT_YET_RECRUITING.

When did EMG and Delta Function in Standard RTSA vs Lateralization start?

EMG and Delta Function in Standard RTSA vs Lateralization started on 2026-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.